(aa) sequence of any one of the strands in the front beta -sheet (fbS),
any of the connecting loops and/or any of the B', I or D strands in the
back beta -sheet (bbS). Also new are: (1) dimers, oligomers and multimers
of (I); (2) isolated DNA (II) that encodes (I); (3) (expression) vectors
containing (II); (4) hosts transformed with the expression vector, and (5)
fusion proteins (FP) of (I) with an immunological adjuvant.
     USE - Cells of (4) are used to produce recombinant (I) which are used
as vaccines for treatment or prevention of diseases associated with
excessive release or activity of (Ia), e.g. rheumatoid arthritis, Crohn's
disease, ulcerative colitis, cancer of any sort, disseminated sclerosis,
diabetes, psoriasis, osteoporosis and asthma. Ab are also useful as
diagnostic immunoassay reagents, while (II) is a source of primers and
probes, and used for expressing (I) in vivo (DNA vaccines).
     ADVANTAGE - (I) have no residual TNF activity, are immunogenic in a
large proportion of the human population (by using promiscuous epitopes)
and are optimised for production of neutralising Ab.
     Dwg.5a4/16
FS   CPI
FA   AB; GI
MC · CPI: B04-E02B; B04-E08; B04-F0100E; B04-G02; B04-G21; B04-H08; B04-H0800E;
        B11-C07A; B12-K04A; B14-C09B; B14-E10C; B14-H01; B14-K01A;
        B14-N01; B14-N17; B14-S04; B14-S11; D05-H07; D05-H09; D05-H12B;
        D05-H12C; D05-H12D1; D05-H12E; D05-H14; D05-H17A5; D05-H17B2;
        D05-H17C

=> d his

     (FILE 'HOME' ENTERED AT 14:08:18 ON 05 JUL 2006)

     FILE 'HCAPLUS' ENTERED AT 14:08:26 ON 05 JUL 2006
                 E T CELLS/CT
                 E E3+ALL
                 E E2
L1   64804 E3-26
                 E E3+ALL
L2   115894 E25+OLD,NT
                 E TUMOR ANTIGEN/CT
L3   4738 E6-14
                 E E6+ALL
L4   36596 E5+OLD,NT
                 E CYTOMEGALOVIRUS/CT
                 E E3+ALL
L5   9574 E7+OLD,NT
                 E ADENOVIRUS/CT
                 E E3+ALL
                 E E2
                 E E3+ALL
L6   12821 E5+OLD,NT
                 E HUMAN ADENOVIRUS/CT
                 E E3+ALL
L7   5343 E7+NT
L8   201 L1-2 AND L3-4 AND L5-7
L9   6 L8 AND (BISPECIF? OR BI SPECIF?)
                 E ANTIGENS/CT
                 E E3+ALL
L10   23628 E2+NT (L)VIR?
L11   376 L1-2 AND L3-4 AND L10
L12   8 L11 AND (BISPECIF? OR BI SPECIF?)
L13   7 L12 NOT L9
                 SEL AN 1-2
L14   2 E1-4 AND L13

     FILE 'WPIX' ENTERED AT 14:42:09 ON 05 JUL 2006
                 E COOPER L/AU

```
L15        123 E3-22
               E JENSEN M/AU
L16        314 E3-29
L17        265 (CITY (1N)HOPE)/PA,CS
               E CITY/PACO
               E E3+ALL
L18        264 CITY/PACO
L19       8053 (B04-B04D1 OR C04-B04D1 OR B04-F04 OR C04-F04)/MC
L20      19132 S T CELL# OR LYMPHOCYT?
L21      97277 (B14-H? OR C14-H? OR B12-G05 OR C12-G05 OR B12-G07 OR C12-G07)/
L22      25313 A61P035/IPC,IC,ICM,ICS,ICA,ICI
L23        317 (B04-B04C8 OR C04-B04C8)/MC
L24      62302 (B14-A02? OR C14-A02? OR B14-A06 OR C14-A06)/MC OR (V560 OR P21
L25      10912 (A61P031-12 OR A61P031-14 OR A61P031-16 OR A61P031-18 OR A61P03
L26         42 (A61P031:12 OR A61P031:14 OR A61P031:16 OR A61P031:18 OR A61P03
L27       1626 L19 AND L21-22
L28         30 L19 AND L23
L29          0 L27-28 AND L15-18
L30         41 L15-18 AND L19-20
L31         12 L30 AND L21-23
L32          0 L31 AND L24-26
L33        445 L27 AND L24-26
L34          4 L28 AND L24-26
L35        183 L33 NOT (PY>2003 OR AY>2003 OR PRY>2003)
L36          2 L35 AND (BISPECIF? OR BI SPECIF?)

=>
```

```
        *T-Lymphocytes, Cytotoxic: IM, immunology
         T-Lymphocytes, Cytotoxic: ME, metabolism
CN       0 (Antigens, Differentiation, T-Lymphocyte); 0 (Antigens, Ly); 0
         (Antigens, Neoplasm); 0 (Antigens, Surface); 0 (Epitopes); 0 (H-2
         Antigens); 0 (Histocompatibility Antigens Class II); 0 (Monokines); 0
         (Proteins)


=> d his

        (FILE 'HOME' ENTERED AT 12:36:49 ON 05 JUL 2006)

        FILE 'MEDLINE' ENTERED AT 12:39:30 ON 05 JUL 2006
                        E COOPER L/AU
L1            487 E3-27,E36
                        E JENSEN  M/AU
                        E JENSEN M/AU
L2            988 E3-27
                        E JENSEN MI/AU
L3             79 E4-14
L4           2556 (CITY(1N)HOPE)/CS
                        E T-CELL/CT
                        E E3+ALL
                        E E2
                        E E3+ALL
L5         184732 E16+NT
                        E T-CELL/CT
                        E E7+ALL
                        E E2
                        E E3+ALL
L6          26481 E8+NT
                        E E31
L7         191321 L5-6
L8            150 L1-4 AND L7
                        E TUMOR ANTIGEN/CT
                        E E4+ALL
                        E E2
                        E E3+ALL
L9          63574 E4+NT
L10             8 L8 AND L9
L11          5573 L7 AND L9
                        E VIRAL ANTIGENS/CT
                        E E3+ALL
                        E E2+ALL
L12         75227 E4+NT
                        E INFLUENZA/CT
                        E INFLUENZA VIRUS/CT
                        E E3+ALL
                        E E2
                        E E3+ALL
L13         21153 E7+NT
                        E CMV/CT
                        E CYATOMEGALOVIRUS/CT
                        E CYTOMEGALOVIRUS/CT
                        E E3+ALL
L14         12567 E9
L15           478 L11 AND L12-14
L16             3 L15 AND (BISPECIF? OR BI SPECIF?)
L17           427 L15 AND PY<=2003
L18           472 L5 AND L9 AND L12-14
L19            43 L18 AND L6
L20             0 L19 AND L1-4
L21            37 L19 AND PY<=2003
                        SEL AN 4 L21
L22             1 E1 AND L21
L23             0 L10 AND L12-14
```

```
L24              9 L10,L22

     FILE 'EMBASE' ENTERED AT 13:04:59 ON 05 JUL 2006
                 E  T-CELL/CT
                 E  T CELL/CT
                 E  E3+ALL
                 E  E2
                 E  E3+ALL
L25         170439 E22+NT
                 E  T CELL/CT
                 E  E42+ALL
                 E  E2
                 E  E3+ALL
L26          20167 E1
                 E  TUMOR ANTIGEN/CT
                 E  E3+ALL
L27          62056 E13+NT
                 E  VIRAL ANTIGEN/CT
                 E  E3+ALL
                 E  E2+ALL
L28          36303 E18+NT
                 E  INFLUENZA/CT
                 E  E3+ALL
L29          11331 E2
                 E  INFLUENZA VIRUS/CT
                 E  E3+ALL
L30          15248 E5+NT
L31            181 L25 AND L27 AND L28-30
L32             13 L31 AND L26
L33              1 L31 AND (BISPECIF? OR BI SPECIF?)
L34            167 L31 NOT L32-33
L35            132 L34 AND PY<=2003

=> b hcap
FILE 'HCAPLUS' ENTERED AT 14:21:49 ON 05 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE COVERS 1907 - 5 Jul 2006  VOL 145 ISS 2
FILE LAST UPDATED: 4 Jul 2006  (20060704/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all 114 tot

L14   ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2006 ACS on STN
AN    2003:610065  HCAPLUS
DN    139:148464
ED    Entered STN:  08 Aug 2003
TI    Bi-specific chimeric T cells for adoptive
      immunotherapy
```

FBL-immune spleen cells with αL3T4 plus complement before culture,
as well as the direct addition of αL3T4 to cultures, diminished the
generation of FBL-specific CTL. The contribution of L3T4+ cells could be
completely replaced by the addition of exogenous cytokines. The data
demonstrate that the optimal generation of FBL-specific Lyt-2+ CTL
requires the presence of L3T4+ cells, presumably to provide necessary
lymphokines. FBL-specific CTL could not be generated from purified
FBL-immune T cells in the absence of AC. Syngeneic Ia+ macrophages
(M.vphi.), added at the initiation of culture, restored the response of
purified T cells. Pretreatment of M.vphi. with ammonium chloride or
chloroquine, or the addition of monoclonal αI-Ab antibody at the
initiation of culture, inhibited the ability of M.vphi. to reconstitute
the CTL response. Finally, the addition of exogenous helper factors could
replace M.vphi. and reconstitute the FBL-specific response of AC-depleted
immune T cells. These results suggest that during the generation of
Lyt-2+ CTL to a syngeneic tumor expressing only class I major
histocompatibility complex antigens, Ia+ AC are required to biochem.
process antigen released from the tumor cells and present this modified
antigen to class II-restricted T helper cells.

ST   cytotoxic T lymphocyte class II antigen; tumor antigen cytotoxic T
      lymphocyte
IT   Neoplasm
          (cytotoxic T-lymphocytes specific for, generation of, accessory and
          helper cells and factors in)
IT   Macrophage
          (in cytotoxic T-lymphocyte generation)
IT   Lymphocyte
          (T-, cytotoxic, formation of, accessory and helper cells and
          factors in, in immune response to tumor)
IT   Lymphocyte
          (T-, helper, helper lymphokine of, in cytotoxic T
          -lymphocyte generation)
IT   Lymphokines and Cytokines
      RL: BIOL (Biological study)
          (helper factor, in cytotoxic T-lymphocyte generation, in immune
          response to tumor)
IT   Antigens
      RL: BIOL (Biological study)
          (histocompatibility, class II, in cytotoxic T-lymphocyte generation, in
          immune response to tumor)

=> d his

      (FILE 'HOME' ENTERED AT 10:39:01 ON 05 JUL 2006)

      FILE 'HCAPLUS' ENTERED AT 10:39:08 ON 05 JUL 2006
L1   2 US2005129671/PN OR (US2004-797609 OR US2003-453197#)/AP,PRN
                E COOPER L/AU
L2   174 E3-24
                E COOPER LAURENCE/AU
L3   27 E3-6
                E COOPER LAWRENCE/AU
L4   6 E4-9
                E JENSEN M/AU
L5   395 E3-36
                E JENSEN MIKE/AU
L6   2 E3
                E JENSEN MICHAEL/AU
L7   397 E3-31
L8   3491 (CITY (1N)HOPE)/CS,PA
                E T CELL/CT
L9   64804 E8-31
                E E8+ALL
L10   115894 E25+OLD,NT
L11   115894 L9-10

```
                 E ANTIGEN/CT
                 E ANTIGENS/CT
                 E E3+ALL
L12      286310  E2+NT
                 E E81+ALL
L13       23367  E11+OLD,NT
                 E ANTIGEN-PRESENTING CELL/CT
                 E E3+ALL
L14       15438  E6+NT
                 E TUMOR ANTIGENS/CT
L15        4738  E3-11
                 E E3+ALL
L16       36596  E5+OLD,NT
L17        4461  L11 AND L15-16
                 E VIRAL ANTIGENS/CT
L18        4461  L17 AND L12-14
                 E INFLUENZA/CT
                 E E3+ALL
L19        2350  E3
                 E INFLUENZA/CT
                 E E6+ALL
L20        5083  E8+OLD
                 E INFLUENZA B VIRUS/CT
                 E E9+ALL
L21       12161  E7+OLD,NT
                 E EBV/CT
                 E E3+ALL
                 E E2
L22        9203  E3-9
                 E E3+ALL
L23        8256  E8+OLD
                 E LYMPHOCRYPTOVIRUS/CT
                 E E3+ALL
                 E HUMAN HERPESVIRUS 5/CT
                 E E3+ALL
L24        4280  E8+OLD
                 E HUMAN HERPESVIRUS 6+ALL/CT
L25         866  E8+OLD,NT
                 E HUMAN HERPESVIRUS 7/CT
                 E E3+ALL
L26         340  E7+OLD
                 E HUMAN HERPESVIRUS 8/CT
                 E E3+ALL
L27        1421  E8
L28          12  L18 AND L1-8
L29         268  L18 AND L19-27
L30         235  L29 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
L31           7  L30 AND (BISPECIF? OR BI SPECIF?)
L32           1  L31 AND L1-8
L33           6  L31 NOT L32
                 SEL AN 3
L34           1  E1-2 AND L33
L35          13  L28,L34
```

     FILE 'HCAPLUS' ENTERED AT 11:03:45 ON 05 JUL 2006

=> b medl
FILE 'MEDLINE' ENTERED AT 13:04:42 ON 05 JUL 2006

 FILE LAST UPDATED: 4 JUL 2006 (20060704/UP). FILE COVERS 1950 TO DATE.

 On December 11, 2005, the 2006 MeSH terms were loaded.

 The MEDLINE reload for 2006 is now (26 Feb.) available. For details
 on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).
 See also: